Catalyst Funds Management Pty Ltd Takes $2.01 Million Position in Biogen Inc. $BIIB

Catalyst Funds Management Pty Ltd bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,400 shares of the biotechnology company’s stock, valued at approximately $2,006,000.

Several other institutional investors also recently made changes to their positions in the stock. Coldstream Capital Management Inc. grew its holdings in shares of Biogen by 6.7% during the fourth quarter. Coldstream Capital Management Inc. now owns 4,782 shares of the biotechnology company’s stock valued at $842,000 after purchasing an additional 302 shares during the last quarter. Jefferies Financial Group Inc. grew its holdings in Biogen by 6.3% in the 4th quarter. Jefferies Financial Group Inc. now owns 32,513 shares of the biotechnology company’s stock worth $5,722,000 after buying an additional 1,913 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Biogen by 6.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $422,000 after buying an additional 151 shares in the last quarter. LSV Asset Management grew its holdings in Biogen by 3.3% in the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after buying an additional 9,976 shares in the last quarter. Finally, Evoke Wealth LLC grew its holdings in Biogen by 1.3% in the 4th quarter. Evoke Wealth LLC now owns 13,543 shares of the biotechnology company’s stock worth $2,383,000 after buying an additional 171 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s stock may be getting some support from analyst commentary suggesting the recent sell-off could be overdone, with one report saying the trial results were better than first reported and that longer-term optimism remains intact. Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
• Neutral Sentiment: Denali said it will keep running a separate Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant, which preserves some optionality for the broader program but does not offset the failure in idiopathic Parkinson’s disease. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• Negative Sentiment: The failed Parkinson’s trial has also sparked investor concern and legal scrutiny, with multiple alerts and investigations following the disclosure, adding another overhang to Biogen shares. Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Analyst Ratings Changes

A number of brokerages recently issued reports on BIIB. Wolfe Research set a $231.00 price objective on Biogen in a report on Monday, February 9th. Oppenheimer increased their price objective on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Citigroup increased their price objective on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, The Goldman Sachs Group increased their price objective on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $193.76 on Friday. The stock has a fifty day moving average price of $185.48 and a two-hundred day moving average price of $180.75. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The firm has a market cap of $28.61 billion, a P/E ratio of 20.79, a PEG ratio of 1.71 and a beta of 0.19. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the company posted $3.02 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts forecast that Biogen Inc. will post 14.18 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.